切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2009, Vol. 03 ›› Issue (03) : 223 -226. doi: 10.3877/cma.j.issn.1674-0793.2009.03.013

论著

进展期结肠癌术后腹腔低渗热灌注联合静脉化疗的临床研究
关晓东1,(), 李坚1, 贾英斌1, 苏永辉1, 钟宏城1   
  1. 1.519000 珠海,中山大学第五附属医院普外三科
  • 收稿日期:2009-04-07 出版日期:2009-06-01
  • 通信作者: 关晓东

Hyperthermic intraperitoneal chemotherapy combined with venous chemotherapy for advanced colon cancer

Xiao-dong GUAN1,(), Jian LI1, Ying-bin JIA1, Yong-hui SU1, Hong-cheng ZHONG1   

  1. 1.Department of General Surgery Ⅲ,the Fifth Affiliated Hospital of Sun Yat-sen University,Zhuhai 519000,China
  • Received:2009-04-07 Published:2009-06-01
  • Corresponding author: Xiao-dong GUAN
引用本文:

关晓东, 李坚, 贾英斌, 苏永辉, 钟宏城. 进展期结肠癌术后腹腔低渗热灌注联合静脉化疗的临床研究[J/OL]. 中华普通外科学文献(电子版), 2009, 03(03): 223-226.

Xiao-dong GUAN, Jian LI, Ying-bin JIA, Yong-hui SU, Hong-cheng ZHONG. Hyperthermic intraperitoneal chemotherapy combined with venous chemotherapy for advanced colon cancer[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2009, 03(03): 223-226.

目的

观察进展期结肠癌患者术后早期腹腔低渗热灌注(HIPEC)联合静脉化疗的临床治疗效果。

方法

将89例进展期结肠癌患者随机分为HIPEC联合全身化疗组44例(试验组)及单纯全身化疗组45例(对照组)。根治性结肠癌切除术后,试验组行HIPEC 4次后,进行FOLFOX6静脉化疗方案。对照组则行单纯FOLFOX6化疗方案进行静脉化疗。对照观察分析两组的临床效果与预后。

结果

两组均无发生严重并发症。试验组KPS评分升高率为54.54%,对照组为40.00%,差异比较有统计学意义(P<0.05);试验组术后1、3、5年生存率分别为96.8%、72.3%、52.3%,对照组分别为95.7%、65.4%、43.0%,两组术后3、5年生存率比较,差异有统计学意义(P<0.05)。

结论

HIPEC联合静脉化疗能较有效地提高结肠癌术后生存率和生存质量,是结肠癌综合治疗中较为合理的手术后辅助治疗方式。

Objective

To evaluate the clinical effects of hyperthermic intraperitoneal chemotherapy(HIPEC) combined with venous chemotherapy for the treatment of advanced colon cancer.

Methods

Eighty-nine cases of advanced colon cancer were randomly divided into experiment group (44 cases)and control group(45 cases).One week after radical colonectomy,HIPEC was used four times,then the FOLFOX6 chemotherapy plan was carried out monthly for six months in experiment group. Whereas the control group was received FOLFOX6 chemotherapy plan monthly for six months only.The postoperative survival rate(1-,3-and 5-year)and KPS scores of patients were compared between the two groups.

Results

There were no severe complications occurred in two groups.KPS scale increasing rate was 53.65%in experiment group and 40.00%in control group respectively(P<0.05).The 1-,3-and 5-year survival rates in treatment group were 96.8%,72.3%,52.3%and 95.7%,65.4%,43.0%in control group respectively.The 3-and 5-year survival rates achieved statistical significance between the two groups (P <0.05).

Conclusion

Combined with venous chemotherapy, HIPEC can improve the prognosis and raise survivalrate of the advanced colon cancer patients significantly.

表1 两组病例临床资料比较(例)
表2 治疗后KPS 评分变化比较(例)
1
万德森.结直肠癌根治术中化疗的研究概况.癌症,2000,19(120):1068-1071.
2
黎介寿,吴孟超.普通外科手术学.2 版.北京:人民军医出版社,2005.476-500.
3
Deraco M,Laterza B,Kusamura S,et al.Updated treatment of peritoneal carcinomas:a review.Minerva Chir,2007,62(6):459-476.
4
Esquivel J,Elias D,Baratti D,et al.Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination.J Surg Oncol,2008,98(4):263-267.
5
Kusamura S,Dominique E, Baratti D, et al. Drugs carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol, 2008,98(4):247-252.
6
Zylberberg B,Ravina JH,Barous JS,et al.Chemotherapy by intravenous and intraperitoneal routes combined in ovarian cancer.Gynecol Oncol,1990,36(2):271-276.
7
韩忠华,池畔.结直肠癌术后腹腔化疗并发症及其防治.结直肠肛门外科,2008,14(3):209-212.
8
Schmidt U,Dahlke MH,Klempnauer J,et al.Perioperative morbidity and quality of life in long term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Eur J Surg Oncol,2005,31(1):53-58.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[7] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[8] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[9] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[10] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[11] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[12] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[13] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要